RxDoctor Payments Data

Tammis Seipel, MD

Internal Medicine · Virginia Beach, VANPI 1962454603

Payments from drug & device makers

$8,331in general payments, 2019–2025

Across 402 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$867
  • AstraZeneca$801
  • Novo Nordisk$791
  • Lilly USA, LLC$511
  • Johnson & Johnson$375
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,325100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,331 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$247,097
Medicare patients
653
Services billed
3,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$74,470
EliquisApixaban51$67,052
TrulicityDulaglutide44$58,703
RybelsusSemaglutide15$29,424
JanuviaSitagliptin Phosphate18$25,467
JardianceEmpagliflozin17$19,829
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,024
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$11,544
Breo ElliptaFluticasone/Vilanterol18$10,759
Spiriva RespimatTiotropium Bromide12$10,232
Atorvastatin Calcium413$4,171
Rosuvastatin Calcium154$3,736
Levothyroxine Sodium328$3,122
Pantoprazole Sodium51$2,672
Amlodipine Besylate352$2,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$791$103,89460 claims
PfizerEliquis$867$67,05251 claims
Lilly USA, LLCTrulicity$511$58,70344 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$129$38,32755 claims
Boehringer IngelheimJardiance, Spiriva Respimat$216$30,06129 claims
MerckJanuvia$196$25,46718 claims
AbbVieSynthroid$1,348$2,15741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →